Skin cancer drug pembrolizumab hailed as 'miraculous' new treatment

'Promising treatment' revealed to boost survival rates of melanoma from one in ten to nearly three in four

A pioneering new drug appears to have cured a British man with advanced skin cancer who had been given just months to live.

Doctors cannot be certain it was the treatment that led to the "miraculous" outcome for 64-year-old Warwick Steele, but know of no other explanation.

Results from an early-stage trial of the drug indicate that it may offer a potential "paradigm shift" in cancer therapy, according to Mr Steele's consultant.

The drug, pembrolizumab, is the latest in a new generation of treatments that prevent cancers shielding themselves from the immune system.

It was tested on melanoma - the most dangerous form of skin cancer - because the prospects for patients with advanced forms of this disease are so bleak.

Just under 70 per cent of the 411 patients taking part in the trial were still alive one year after starting on the treatment.

The result is considered remarkable because all had highly advanced melanoma and a very poor prognosis.

Currently one-year survival rates for untreated patients diagnosed with advanced stage four melanoma are just 10% for men and 35% for women.

Mr Steele, a television engineer from Ruislip, west London, had undergone six months of treatment with pembrolizumab, which is injected into the bloodstream.

Doctors were astonished when after just three months his tumours had almost disappeared. Since then they have shown no sign of returning - and in fact have shrunk even further.

His consultant, Dr David Chao, from the Royal Free Hampstead NHS Trust in London, said: "We cannot say for certain that he's been cured, but he is doing very well. He was aware that without an effective treatment his survival prospects were not good - maybe months.

"Pembrolizumab looks like it has potential to be a paradigm shift for cancer therapy and is firmly helping to establish immunotherapy as one of the most exciting and promising treatment modalities in recent years.

"This is one of several new drugs of this type being produced. What these early trials are showing is that they are fulfilling their promise ridiculously fast.

"Some of these results are really astonishing; almost jaw-dropping. And these drugs may be applicable to many different cancer types, including ones that are hard to treat, such as lung cancer.

"Cancers adapt to treatments, and when they come back they are harder to treat. Can we dream about actually curing some of our patients with very advanced cancer? Once we get the immune system attacking the cancer, can it act independently to keep the cancer under control? We don't have all the answers yet, but that's what we're looking at."

Pembrolizumab is a synthetic antibody that blocks a biological pathway called programmed cell death 1 (PD-1) which cancers activate to suppress the immune system.

In healthy individuals, PD-1 is part of the process that applies a "brake" to the immune system and prevents it running out of control.

Without the brake, there is a risk of a harmful inflammatory reaction - a potential serious side-effect of the new drugs.

Pembrolizumab was generally "well tolerated" by the trial patients, according to Dr Chao, but he said responses varied widely between individuals.

Results from the trial were presented at the annual meeting of the American Society of Clinical Oncology in Chicago.

Clinicians do not yet know the true extent of how pembrolizumab might affect survival. After 18 months, 62% of patients were still alive and undergoing treatment.

In addition, around 80% of patients responded to the drug - an unusually high proportion.

A total of 72% experienced tumour shrinkage, including 39% whose tumours were more than halved in size, according to one kind of assessment.

Additional data showed that the drug also reduced the size of advanced non-small cell lung cancers by up to 47%.

Pembrolizumab's manufacturer, the pharmaceutical company Merck Sharp & Dohme, is expected to apply for a European licence to market the drug within months.

Each year, around 13,300 people in the UK are diagnosed with melanoma - more than a third of them aged under 55.

Gillian Nuttall, founder of the charity Melanoma UK, said: "Advanced melanoma is a terrible disease with a poor prognosis. Pembrolizumab represents the latest advance in a whole raft of new treatments in advanced melanoma which have come through over the past few years.

"The pembrolizumab results are really exciting and could represent a turning point for patients affected by advanced melanoma, giving them a greater chance of survival."

PA

Life and Style
ebookNow available in paperback
ebooks
ebookPart of The Independent’s new eBook series The Great Composers
Life and Style
Living for the moment: Julianne Moore playing Alzheimer’s sufferer Alice
health
News
Jay Z
businessJay-Z's bid for Spotify rival could be blocked
News
The spider makes its break for freedom
VIDEO
Voices
A propaganda video shows Isis forces near Tikrit
voicesAdam Walker: The Koran has violent passages, but it also has others that explicitly tells us how to interpret them
Sport
Ashley Young celebrates the winner for Manchester United against Newcastle
footballNewcastle v United player ratings
Arts and Entertainment
books
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: 1st Line Customer Support Technician

    £15000 - £19000 per annum: Recruitment Genius: This Waterlooville based softwa...

    Ashdown Group: C# Developer - (C#, VB.Net, SQL, Git, TDD)

    Negotiable: Ashdown Group: Developer (C#, VB & ASP.Net, SQL Server, TSQL) - Pe...

    Recruitment Genius: Associate Sales Consultant

    £16000 - £19000 per annum: Recruitment Genius: An Associate Sales Consultant i...

    Recruitment Genius: Operations Manager

    £25000 - £35000 per annum: Recruitment Genius: Well established and expanding ...

    Day In a Page

    War with Isis: Iraq's government fights to win back Tikrit from militants - but then what?

    Baghdad fights to win back Tikrit from Isis – but then what?

    Patrick Cockburn reports from Kirkuk on a conflict which sectarianism has made intractable
    Living with Alzheimer's: What is it really like to be diagnosed with early-onset dementia?

    What is it like to live with Alzheimer's?

    Depicting early-onset Alzheimer's, the film 'Still Alice' had a profound effect on Joy Watson, who lives with the illness. She tells Kate Hilpern how she's coped with the diagnosis
    The Internet of Things: Meet the British salesman who gave real-world items a virtual life

    Setting in motion the Internet of Things

    British salesman Kevin Ashton gave real-world items a virtual life
    Election 2015: Latest polling reveals Tories and Labour on course to win the same number of seats - with the SNP holding the balance of power

    Election 2015: A dead heat between Mr Bean and Dick Dastardly!

    Lord Ashcroft reveals latest polling – and which character voters associate with each leader
    Audiences queue up for 'true stories told live' as cult competition The Moth goes global

    Cult competition The Moth goes global

    The non-profit 'slam storytelling' competition was founded in 1997 by the novelist George Dawes Green and has seen Malcolm Gladwell, Salman Rushdie and Molly Ringwald all take their turn at the mic
    Pakistani women come out fighting: A hard-hitting play focuses on female Muslim boxers

    Pakistani women come out fighting

    Hard-hitting new play 'No Guts, No Heart, No Glory' focuses on female Muslim boxers
    Leonora Carrington transcended her stolid background to become an avant garde star

    Surreal deal: Leonora Carrington

    The artist transcended her stolid background to become an avant garde star
    LGBT History Month: Pupils discuss topics from Sappho to same-sex marriage

    Education: LGBT History Month

    Pupils have been discussing topics from Sappho to same-sex marriage
    11 best gel eyeliners

    Go bold this season: 11 best gel eyeliners

    Use an ink pot eyeliner to go bold on the eyes with this season's feline flicked winged liner
    Cricket World Cup 2015: Tournament runs riot to make the event more hit than miss...

    Cricket World Cup runs riot to make the event more hit than miss...

    The tournament has reached its halfway mark and scores of 300 and amazing catches abound. One thing never changes, though – everyone loves beating England
    Katarina Johnson-Thompson: Heptathlete ready to jump at first major title

    Katarina Johnson-Thompson: Ready to jump at first major title

    After her 2014 was ruined by injury, 21-year-old Briton is leading pentathlete going into this week’s European Indoors. Now she intends to turn form into gold
    Syrian conflict is the world's first 'climate change war', say scientists, but it won't be the last one

    Climate change key in Syrian conflict

    And it will trigger more war in future
    How I outwitted the Gestapo

    How I outwitted the Gestapo

    My life as a Jew in wartime Berlin
    The nation's favourite animal revealed

    The nation's favourite animal revealed

    Women like cuddly creatures whilst men like creepy-crawlies
    Is this the way to get young people to vote?

    Getting young people to vote

    From #VOTESELFISH to Bite the Ballot